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Epilepsy, one of the most prevalent neurological conditions, presents as a complex
disorder of network homeostasis characterized by spontaneous non-provoked seizures
and associated comorbidities. Currently used antiepileptic drugs have been designed to
suppress neuronal hyperexcitability and thereby to suppress epileptic seizures. However,
the current armamentarium of antiepileptic drugs is not effective in over 30% of patients,
does not affect the comorbidities of epilepsy, and does not prevent the development
and progression of epilepsy (epileptogenesis). Prevention of epilepsy and its progression
remains the Holy Grail for epilepsy research and therapy development, requiring novel
conceptual advances to find a solution to this urgent medical need. The methylation
hypothesis of epileptogenesis suggests that changes in DNA methylation are implicated
in the progression of the disease. In particular, global DNA hypermethylation appears
to be associated with chronic epilepsy. Clinical as well as experimental evidence
demonstrates that epilepsy and its progression can be prevented by biochemical
manipulations and those that target previously unrecognized epigenetic functions
contributing to epilepsy development and maintenance of the epileptic state. This
mini-review will discuss, epigenetic mechanisms implicated in epileptogenesis and
biochemical interactions between adenosine and glycine as a conceptual advance
to understand the contribution of maladaptive changes in biochemistry as a major
contributing factor to the development of epilepsy. New findings based on biochemical
manipulation of the DNA methylome suggest that: (i) epigenetic mechanisms play a
functional role in epileptogenesis; and (ii) therapeutic reconstruction of the epigenome
is an effective antiepileptogenic therapy.
Keywords: epilepsy, epileptogenesis, adenosine, adenosine kinase, glycine, glycine transporter 1, epigenetics,
DNA methylation
INTRODUCTION
Biological evolution is thought to have started with relatively simple, versatile, and
multifunctional metabolites (Miller and Urey, 1959a,b). Adenosine was likely part of the
‘‘primordial soup’’ at the origin of life on Earth (Oro, 1961). Therefore it is not surprising
that adenosine is an integral component of ATP, RNA (including poly-A tails), NAD,
and other compounds essential for basic biochemistry and mitochondrial bioenergetics.
Glycine in turn is the most primitive amino acid, which has additional biochemical
functions in carbon metabolism. It is highly likely that the biochemical and epigenetic
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FIGURE 1 | The “pyramid of life”. Evolutionary complexity started with key
metabolites and biochemical mechanisms, which form the basis of all forms of
life. In contrast, conventional drug development follows a top-down approach.
GPCR’s, G protein coupled receptors.
control of genes through global biochemical regulation preceded
the ‘‘invention’’ of transcription factors, which later assumed the
role to fine-tune a preexisting primordial biochemistry-based
regulatory system. For example, an energy crisis would lower
ATP needed for RNA synthesis and increase adenosine, thereby
promoting increased DNA methylation as will be discussed in
this mini-review in more detail. Both processes would reduce
gene transcription globally and conserve energy. Therefore,
primordial regulatory networks acting on a global homeostatic
level likely preceded the ‘‘invention’’ of gene specific mechanisms
that require sophisticated control through transcription factors,
which in turn are regulated by G protein coupled receptors
(GPCRs) and protein kinase pathways. In contrast, therapy
development conventionally starts with the pharmacology of
drugs. For example, benzodiazepines were almost discovered
by chance in 1957 leading to the subsequent characterization
of the ‘‘benzodiazepine receptor’’ in the CNS in 1977. It
turned out that the benzodiazepine binding site was in fact
an integral part of the GABAA receptor complex (Möhler
and Okada, 1977). Drug-driven therapy development led to a
major focus on ‘‘druggable’’ GPCRs, ion channels, and protein
kinases, which still form the main-stay of CNS therapeutics
today. Methods to exploit gene regulation therapeutically are
still in its infancy and the therapeutic potential of epigenetic,
biochemical, and metabolomic approaches constitutes a new
frontier in therapy development. If the basis of the pyramid
depicted in Figure 1 is overlooked, it becomes obvious that a
traditional pharmacological top-down treatment approach has
limitations.
THE BIOCHEMISTRY OF EPILEPSY
In the following, I will focus on temporal lobe epilepsy (TLE),
the most common form of epilepsy in adult patients, and the
most thoroughly studied form of epilepsy in animal models,
as well as on two key metabolites, adenosine and glycine,
whose homeostasis is known to be affected in the epileptic
brain. Adenosine, primarily through activation of adenosine
A1 receptors, is an endogenous anticonvulsant and seizure
terminator of the brain (Dragunow, 1991; During and Spencer,
1992) that also controls a wide range of cognitive and psychiatric
phenotypes (Boison et al., 2012). In human surgical specimens,
as well as in rodent models of TLE, overexpression of adenosine
kinase (ADK) and resulting adenosine deficiency associate with
astrogliosis and constitute a pathological hallmark of TLE
(Riban et al., 2002; Gouder et al., 2004; Fedele et al., 2005;
Boison, 2008; Li et al., 2008, 2012; Aronica et al., 2011, 2013).
Consequently, therapeutic adenosine augmentation effectively
suppresses seizures in a wide range of rodent models of epilepsy
(Huber et al., 2001; Zuchora et al., 2001; Gouder et al., 2003;
Anschel et al., 2004; Vianna et al., 2005; Li et al., 2007b, 2008;
Wilz et al., 2008; Boison, 2009, 2012a; Boison and Stewart, 2009;
Van Dycke et al., 2010). A focus of this mini-review however
is the underappreciated biochemical adenosine receptor (AR)
independent effects of adenosine that are tightly linked to the
control of DNA methylation and that are under the control of
ADK, an enzyme which also has a specific isoform expressed
in the nucleus of cells (Boison, 2013). The cytoplasmic isoform
of the enzyme is thought to regulate the homeostatic pool
of adenosine thereby determining the level of AR activation
(Boison and Aronica, 2015), whereas the nuclear isoform of
the enzyme strongly affects DNA methylation status (Williams-
Karnesky et al., 2013). Interestingly, ADK undergoes biphasic
expression changes during epileptogenesis in modeled TLE
(Gouder et al., 2004; Li et al., 2008; Boison, 2013), which
form the basis of the ADK hypothesis of epileptogenesis: Acute
insults to the brain such as traumatic brain injury (Clark
et al., 1997), seizures (During and Spencer, 1992; Gouder et al.,
2004), or a stroke (Pignataro et al., 2008) lead to an acute
surge in adenosine associated with transient downregulation
of ADK within the first 2 to 3 h after the injury (Gouder
et al., 2004; Pignataro et al., 2008). This acute phase is followed
by a ‘‘latent period’’ of epileptogenesis, which occurs during
the first few days or weeks after an insult in rodent models,
or weeks and months in humans. During this latent period,
inflammatory processes are activated that lead to microglial and
astroglial activation (Nabbout et al., 2011; Vezzani et al., 2011;
Devinsky et al., 2013). Astrogliosis is associated with increases
in ADK expression and consequential development of adenosine
deficiency. We have previously shown that seizures originate
in areas of astrogliosis with overexpression of ADK (Li et al.,
2008, 2012), that seizure onset during epileptogenesis temporally
coincides with the emergence of astrogliosis and overexpressed
ADK (Li et al., 2007a), that overexpression of ADK as such is
sufficient to generate partial seizures (Li et al., 2007a, 2008), and
that overexpression of ADK triggers hypermethylation of DNA
(Williams-Karnesky et al., 2013). Since therapeutic adenosine
augmentation restores normal DNA methylation levels and
prevents epilepsy progression long-term (Williams-Karnesky
et al., 2013) increased ADK and increased DNA methylation
status might form a vicious cycle implicated in the progression
and maintenance of epilepsy. Therefore, dysregulation of ADK
appears to play a significant role in the processes that turn a
normal brain into an epileptic brain.
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In the hippocampal formation, glycine can exert opposing
effects that depend on the activation of presynaptic (Kubota et al.,
2010; Winkelmann et al., 2014) vs. postsynaptic glycine receptors
(GlyRs; Aroeira et al., 2011). It has recently been demonstrated
(Chen et al., 2014) that low concentrations of glycine
(10 µM) exert pro-convulsive effects, whereas higher glycine
concentrations (100 µM) attenuate recurrent epileptiform
discharges. The pro-convulsive actions of presynaptic GlyRs
expressed on glutamatergic synapses (Winkelmann et al., 2014)
is further supported by findings showing that the expression
of edited GlyR encoding mRNAs are increased in the human
epileptic hippocampus (Eichler et al., 2008) and that GlyR RNA
editing regulates glycine affinity (Meier et al., 2005). These
findings suggest that glycine homeostasis plays a crucial role
in maintaining the balance between increased and decreased
neuronal excitability. Hippocampal glycine is largely regulated
by its reuptake transporter, glycine transporter 1 (GlyT1),
found in both excitatory neurons and astrocytes (Tsai et al.,
2004; Aragón and López-Corcuera, 2005; Cubelos et al., 2005;
Eulenburg et al., 2005; Martina et al., 2005; Betz et al., 2006).
Consequently, the genetic deletion of GlyT1 increased synaptic
glycine availability (Gomeza et al., 2003). Engineered mice with
a genetic deletion of GlyT1 in forebrain were characterized
by a decrease in hippocampal glycine uptake, an increase
in hippocampal NMDAR function, and a wide spectrum of
pro-cognitive effects (Yee et al., 2006; Möhler et al., 2008,
2011). Therefore, GlyT1 is considered a promising target for
the treatment of cognitive symptoms in schizophrenia and
several compounds have been tested in phase II and III
clinical trials (Black et al., 2009; Singer et al., 2009; Möhler
et al., 2011). A recent study (Shen et al., 2015) provided
the first comprehensive analysis of GlyT1 dysregulation in
chronic TLE. GlyT1 expression during epileptogenesis was
characterized as a biphasic response with initial downregulation
of GlyT1 after epileptogenesis-precipitating seizures followed
by sustained pathological overexpression of GlyT1 in chronic
epilepsy as demonstrated in twomechanistically different models
of TLE in mice and rats (Shen et al., 2015). It was further
demonstrated that human TLE is likewise associated with
increased levels of GlyT1. Conversely, the pharmacological
suppression of GlyT1 or the genetic ablation of GlyT1 in
the hippocampus provided robust reduction of both acute
as well as chronic seizure activity in three different model
systems (Shen et al., 2015). Therefore, glycinergic regulation of
network excitability is altered in epilepsy and GlyT1 presents
a rational therapeutic target for the treatment of epilepsy.
Pathological overexpression of GlyT1 in progressive epilepsy also
implies altered interactions of GlyT1 with the transmethylation
pathway (Figure 2), a novel hypothesis further discussed
below.
THE EPIGENETICS OF EPILEPSY
The role of epigenetics in epilepsy development is a new
and emerging research area (Garriga-Canut et al., 2006;
Qureshi and Mehler, 2010; Kobow and Blümcke, 2012;
Lubin, 2012; Henshall and Kobow, 2015). The fact that
FIGURE 2 | S-adenosylmethionine (SAM) dependent transmethylation
pathway, which is under the control of adenosine and glycine.
Adenosine and glycine are regulated by adenosine kinase (ADK) and glycine
transporter 1 (GlyT1), respectively. DNMT, DNA methyltransferase; GNMT,
glycine N-methyltransferase.
epigenetic changes might play a significant role at least in
TLE is important because in contrast to genetic mutations,
epigenetic changes are potentially reversible. The knowledge
of epigenetic mechanisms implicated in the development of
epilepsy provides a conceptual and mechanistic framework
for the future development of epigenetic therapies tailored to
prevent epilepsy (antiepileptogenic) or its progression (disease
modifying). Currently used antiepileptic therapies fail to address
the underlying causes of epilepsy and do not halt epileptogenesis
(Löscher and Brandt, 2010). Epileptogenesis is characterized by
a progressive increase in frequency and severity of spontaneous
recurrent seizures (SRS). Several mechanisms are implicated
in the epileptogenic cascade including neuro-inflammatory
responses, neuronal cell loss, mossy fiber sprouting, aberrant
connectivity, and gliosis coupled with adenosine dysfunction
(Dudek et al., 2002; Seifert et al., 2010; Vezzani et al.,
2011; Aronica et al., 2012; Boison, 2012b). One potential
unifying factor behind many of the pathological changes in
epileptogenesis may be epigenetic modifications, which are
likely further potentiated by epileptogenesis itself (Qureshi
and Mehler, 2010; Kobow and Blümcke, 2011). Epigenetic
modifications, which alter gene transcription without modifying
the underlying DNA sequence, are plastic and can respond
rapidly in response to environmental cues, an important
endogenous mechanism for the control of gene expression.
Changes in histone acetylation and methylation, as well as
changes in DNA methylation have been shown to occur in
mature cells in the central nervous system (CNS; Ma et al., 2009;
Feng et al., 2010). Importantly, these changes occur regularly
and rapidly. Even a single episode of neural synchronization
exceeding 30 s in the hippocampus induces DNA methylation-
dependent alterations in transcription of immediate-early genes
and initiates a cascade of transcription factors contributing to
long-term circuit alterations (Nelson et al., 2008). Therefore,
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epigenetic modifications offer new therapeutic alternatives to
interfere with epileptogenesis.
THE METHYLATION HYPOTHESIS OF
EPILEPTOGENESIS
Although several epigenetic mechanisms such as histone
modifications that involve the addition or removal of methyl
or acetyl groups might be implicated in epileptogenesis
(Henshall and Kobow, 2015), recent evidence points to a
critical role of DNA methylation changes for the development
and progression of epilepsy, which will be discussed in the
following. Altered DNA methylation in the brain has been
implicated in psychiatric, neurodegenerative, and neurological
conditions, including epilepsy (Kobow et al., 2009; Ma
et al., 2009; Feng et al., 2010; Martin and Wong, 2013;
Masliah et al., 2013; Coppieters et al., 2014; Tremolizzo
et al., 2014). The methylation hypothesis of epileptogenesis
suggests that seizures by themselves can induce epigenetic
modifications and thereby aggravate the epileptogenic condition
(Kobow and Blümcke, 2011). Specifically, increased activity
of DNA methylating enzymes as well as hypermethylation
of DNA has been associated with the development of
human and experimental epilepsy (Kobow et al., 2009,
2013; Zhu et al., 2012; Williams-Karnesky et al., 2013;
Miller-Delaney et al., 2015). Thus, interference with DNA
methylation offers novel conceptual opportunities to prevent
epilepsy.
BRAIN HOMEOSTASIS AND THE
CONTROL OF DNA METHYLATION
DNA methylation status depends on the equilibrium of
biochemical enzyme reactions that add methyl groups to
cytidine groups in the DNA (5-methylcytidine, 5mC) catalyzed
by DNA methyltransferases (DNMTs) and those that convert
methyl groups to hydroxymethyl groups catalyzed by Ten-eleven
translocation (TET) enzymes in preparation for active DNA
demethylation. Here I will focus on those mechanisms that
add methyl groups to DNA; those mechanisms are linked to
the S-adenosylmethionine (SAM) dependent transmethylation
pathway (Figure 2), which is under the control of adenosine
and glycine regulated by ADK (Boison et al., 2002; Boison,
2013) and GlyT1 (Gomeza et al., 2003; Yee et al., 2006),
respectively. DNAmethylation requires the donation of a methyl
group from SAM, a process that is facilitated by DNMTs. The
resulting product, S-adenosylhomocysteine (SAH) is then further
converted into adenosine and homocysteine (HCY) by SAH
hydrolase (SAHH). Critically, the equilibrium constant of the
SAHH enzyme lies in the direction of SAH formation (Kredich
and Martin, 1977); therefore, the reaction will only proceed
when adenosine and HCY are constantly removed (Kredich and
Martin, 1977; Boison et al., 2002). If metabolic clearance of
adenosine through ADK is impaired, SAH levels rise (Boison
et al., 2002). SAH in turn inhibits DNMTs through product
inhibition (James et al., 2002). Based on adenosine’s role as
obligatory end product of DNA methylation, we conclude that
an increase in ADK and the resulting decrease in adenosine,
as seen in chronic epilepsy (Li et al., 2008; Masino et al.,
2011), would drive increased global DNA methylation in the
brain. This process may be amplified, because adenosine is
an inhibitor of ADK (Boison, 2013). Therapeutic adenosine
augmentation may thus effectively reverse pathological DNA
hypermethylation and thereby prevent epilepsy progression. The
recent discovery of glycine-N-methyltransferase (GNMT) in the
hippocampus (Carrasco et al., 2014) suggests that the availability
of hippocampal glycine also controls the SAM-dependent
transmethylation pathway by competing for methyl-groups.
Increased GlyT1 as seen in chronic TLE (Shen et al., 2015)
is expected to affect DNA methylation through interference
with glycine homeostasis. Interestingly, the methylation of
glycine leads to the formation of sarcosine, which is an
endogenous inhibitor of GlyT1 (Javitt, 2012). Therapeutic glycine
augmentation (e.g., via diet) may thus effectively divert methyl
groups to the formation of sarcosine and thereby reduce:
(i) pathological DNA hypermethylation; (ii) ameliorate the
effects of pathologically overexpressed GlyT1; and (iii) prevent
epilepsy progression.
TOWARDS EPIGENETIC THERAPIES FOR
EPILEPSY PREVENTION
The antiepileptogenic potential of transient focal adenosine-
delivery was tested in a rat model of systemic kainic acid
(KA)-induced progressive TLE (Williams-Karnesky et al., 2013).
Young male rats (130–150 g) received an acute dose of
KA (12 mg/kg i.p.) to trigger status epilepticus (SE). Only
rats that exhibited at least 3 h of acute convulsive SE
were used further. Rats were subjected to continuous long-
term monitoring to quantify seizure activity. Once rats had
reached a stable rate of 3–4 SRS per week at 9 weeks
post KA, the animals were randomized and each rat received
bilateral intraventricular adenosine-releasing silk-implants, silk-
only implants, or a corresponding sham treatment. Adenosine
releasing implants were designed to transiently deliver a
stable dose of 250 ng adenosine per brain ventricle per
day restricted to 10 days of drug delivery (Szybala et al.,
2009). Twenty four hours after the surgery, continuous video
monitoring was initiated, maintained for 4 weeks, and resumed
after a 4 week hiatus for an additional 4 weeks. In the
control groups seizures continued to increase both in number
and severity. In contrast, in recipients of adenosine-releasing
implants, seizures were almost completely suppressed after
polymer implantation. Remarkably, reduced seizure activity was
maintained far beyond expiration of adenosine-release from
the polymer for at least 12 weeks following implantation.
Even at 12 weeks after implantation, seizure incidence was
reduced by more than 70%. Importantly, and in line with
prolonged reduction of seizures, mossy fiber sprouting at
21 weeks following KAwas significantly attenuated in adenosine-
treated rats compared to controls. In line with those profound
antiepileptogenic effects, the transient delivery of adenosine
restored normal DNA methylation status long-term. These data
demonstrate that the transient delivery of adenosine is sufficient
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to restore normal DNA methylation status and to prevent
epilepsy progression long-term (Williams-Karnesky et al.,
2013).
CONCLUSIONS AND OUTLOOK
The realization that a transient local dose of adenosine can
have long-lasting antiepileptogenic effects based on shifting
the transmethylation equilibrium through mass action may
offer new therapeutic opportunities for small molecule ADK
inhibitors. ADK inhibitors had been in pre-clinical development
in the early 2000’s for the indications of seizure management
in chronic epilepsy, the control of chronic pain and robust
anti-inflammatory effects in chronic conditions (McGaraughty
et al., 2005). Although highly efficient in preclinical models,
further drug development was halted due to unacceptable side
effects related to chronic drug dosing (McGaraughty et al.,
2005). The first generation of ADK inhibitors was designed
to augment beneficial AR dependent effects of adenosine by
raising extracellular levels of adenosine, which are at the
same time responsible for wide-spread systemic adverse effects
of those agents. Of note, patients with inborn global ADK
deficiency develop hepatic encephalopathy and a wide range
of neurological symptoms (Bjursell et al., 2011), however it is
currently not known whether those symptoms are a primary
cause of ADK deficiency in the brain, or secondary to hepatic
encephalopathy. Early drug development efforts created a bias
for the identification of agents with preferential action on the
cytoplasmic isoform of ADK. ADK inhibitors with a higher
selectivity for the nuclear isoform of ADKmight capitalize on the
epigenetic effects of adenosine while minimizing AR-mediated
adverse effects. In addition, the short term use of ADK inhibitors,
over days as opposed to chronic sustained drug dosing, might
be acceptable if long-lasting epigenetically based therapeutic
benefits can be achieved. Challenges for drug development
remain. It needs to be determined whether new therapeutic
agents can enter the brain and whether a higher level of selectivity
for specific isoforms of ADK can be achieved. Due to the different
distribution of nucleoside transporters within the brain there
might be opportunities for the development of cell-type or
isoform selective therapies. Glycine modifying therapies might
constitute an alternative avenue to affect DNA methylation and
potentially epileptogenesis. However, it needs to be determined
how the adenosine and glycine systems interact on the epigenetic
level. As discussed in this mini-review, understanding the
biochemistry of epileptogenesis might light to the development
of novel forms of therapeutic intervention.
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